Frontier IP Advances ASF Vaccine Development
Company Announcements

Frontier IP Advances ASF Vaccine Development

Frontier IP (GB:FIPP) has released an update.

Frontier IP Group plc’s portfolio company, The Vaccine Group, is partnering with The Pirbright Institute to develop a vaccine against African swine fever, a disease threatening global pig populations and food security. The UK’s pig and pork export market stands to benefit from the collaboration, as it is valued at £623 million. The project, supported by UK government funding, will use innovative herpesvirus-based technology in hopes of creating an effective vaccine.

For further insights into GB:FIPP stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks UK Auto-Generated NewsdeskFrontier IP Shareholding Shift Notified
TipRanks UK Auto-Generated NewsdeskFrontier IP Backs Multi-Strain Pig Vaccine Development
TipRanks UK Auto-Generated NewsdeskNandi Proteins Nets £500K Investment Boost
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App